The Science Behind Hormone & Testosterone Supplements

Therapeutic dose: 2,000–4,000 mg/day (often with ~400 mcg folic acid)

See ranked Myo-Inositol products→

• 2024 guideline meta-analysis (30 trials, 19 pooled) found benefits for some metabolic markers and a signal for ovulation in PCOS, but called overall evidence 'limited and inconclusive'.PubMed ↗
• RCT in overweight PCOS women: 2 g/day myo-inositol significantly lowered LH, the LH:FSH ratio, insulin, and HOMA-IR vs folic-acid placebo over 12 weeks — the insulin-androgen mechanism in action.PubMed ↗
• Cochrane review of 13 trials rated the PCOS fertility (live-birth) evidence low-to-very-low quality — uncertain whether myo-inositol improves live birth or pregnancy vs standard care.
• RCT in postmenopausal metabolic-syndrome women: 4 g/day for 12 months improved HOMA-IR, blood pressure, and lipids vs diet alone — benefits cluster in insulin-resistant populations.PubMed ↗

Therapeutic dose: 240–600 mg/day standardized root extract

See ranked Ashwagandha (KSM-66 / Shoden) products→

• RCT in chronically stressed adults: 600 mg/day for 60 days sharply lowered Perceived Stress Scale (p<0.0001) and serum cortisol (p=0.0006) vs placebo — the most-cited stress trial.PubMed ↗
• Industry-funded RCT (Shoden): 240 mg/day for 60 days reduced morning cortisol and Hamilton Anxiety, and raised DHEA-S vs placebo — attributed to HPA-axis modulation.PubMed ↗
• Industry-funded RCT in resistance-training novices: 600 mg/day for 8 weeks raised testosterone +96 ng/dL vs +18 ng/dL placebo (p=0.004) — effect unproven in trained men.PubMed ↗
• RCT in subclinical hypothyroidism: 600 mg/day for 8 weeks normalized TSH (p<0.001) and raised free T3 and T4 — the same thyroid-stimulating effect is a risk in hyperthyroid or medicated patients.PubMed ↗

Therapeutic dose: 200–400 mg/day standardized water extract (Physta/LJ100)

See ranked Tongkat Ali (Eurycoma longifolia) products→

• Meta-analysis of 5 RCTs found tongkat ali raised total testosterone (SMD 1.35, p=0.001), largest in men below 300 ng/dL — but heterogeneity was extreme (I²=87%) with small-study bias flagged.PubMed ↗
• Industry-linked RCT in men 50–70 with testosterone <300 ng/dL: 200 mg/day Physta for 12 weeks raised total testosterone from week 4 and improved aging-symptom and fatigue scores.PubMed ↗
• Industry-supplied RCT in moderately stressed adults: 200 mg/day for 4 weeks lowered salivary cortisol ~16%, raised salivary testosterone ~37%, and improved mood vs placebo.PubMed ↗
• Open pilot in active seniors: 400 mg/day for 5 weeks raised total and free testosterone; in women the free-T rise tracked a drop in SHBG — uncontrolled and hypothesis-generating.PubMed ↗

Therapeutic dose: 500–600 mg/day standardized seed extract (e.g. Testofen, Furosap)

• Double-blind RCT (60 healthy men, 25–52y) of 600 mg/day Testofen for 6 weeks improved self-reported sexual arousal and orgasm; serum testosterone and prolactin stayed within the reference range.PubMed ↗
• 2023 systematic review/meta-analysis (7 studies, 449 participants) found only a small effect on total (SMD ~0.32) and free testosterone (SMD ~0.24) in men — modest and heterogeneous.PubMed ↗
• Positive trials cluster around branded extracts (Testofen, Furosap) funded by the makers, and effects are mostly on subjective libido scores rather than confirmed testosterone elevation.

Therapeutic dose: 8–11 mg/day (RDA); repletion in deficiency, not routine high-dose

See ranked Zinc products→

• In zinc-deficient men, repletion improves sperm count and motility and modestly raises testosterone; in zinc-replete men, supplementation does not raise testosterone or improve fertility.
• Zinc is highly concentrated in seminal fluid and required for spermatogenesis and Leydig-cell testosterone production — severe deficiency lowers serum testosterone and impairs sperm production.
• Acrodermatitis enteropathica (genetic zinc malabsorption) causes hypogonadism and is fatal untreated; lifelong zinc fully reverses it — the cleanest proof zinc is essential, not a generic booster.
• The popular 'zinc raises testosterone in everyone' claim does not survive trials in non-deficient men — it is a repletion effect, real for the deficient and false for the replete.

Therapeutic dose: 150 mcg/day (pregnancy/RDA); UL 1,100 mcg/day — avoid kelp mega-doses

See ranked Iodine products→

• Iodine is the irreplaceable atomic component of thyroxine (T4) and triiodothyronine (T3) — without it the thyroid cannot synthesize hormone at all.
• Universal salt iodization eliminated endemic goiter and cretinism in formerly deficient regions — one of the strongest population-level thyroid interventions of the 20th century.PubMed ↗
• In iodine-replete populations, supranormal intake (kelp, mega-dosed supplements, amiodarone) drives iodine-induced hyperthyroidism in nodular disease and worsens Hashimoto's — the dose-response is U-shaped.
• Kelp and seaweed supplements deliver iodine from negligible to thousands of micrograms per serving — above the 1,100 mcg/day upper limit — with documented thyroid dysfunction; pharmaceutical potassium iodide is predictable.

Therapeutic dose: ~200 mcg/day (Hashimoto's contexts); stay at/below RDA otherwise (UL 400 mcg/day)

See ranked Selenium products→

• Pooled trials in Hashimoto's patients found modest reductions in anti-TPO antibody titers with 200 mcg/day over 3–6 months; effects on TSH and free T4 were small and inconsistent.PubMed ↗
• Anti-TPO antibody titer is a surrogate marker — it can drop without clinical thyroid function meaningfully changing, and long-term outcomes (progression to hypothyroidism) are undemonstrated.
• Iodothyronine deiodinases that convert T4 to active T3 are selenoproteins, and the thyroid holds the body's highest tissue selenium — the mechanistic basis for the autoimmune-thyroid signal.
• NPC trial secondary analysis: 200 mcg/day selenium increased incident type 2 diabetes, concentrated in those with the highest baseline selenium — a reason not to mega-dose in the replete.PubMed ↗

Therapeutic dose: Best used in a 40:1 myo-inositol : D-chiro-inositol ratio; high-dose DCI alone is not advised

See ranked D-Chiro-Inositol products→

• Early RCTs reported DCI lowered free testosterone and improved ovulation/insulin sensitivity in women with PCOS — the basis for its use as a PCOS androgen-lowering agent.
• The 'DCI paradox': high DCI in follicular fluid is associated with WORSE oocyte quality, because ovarian granulosa cells need myo-inositol — so high-dose DCI alone can harm egg quality.
• Comparative trials favor myo-inositol or a 40:1 myo:DCI blend over DCI alone for restoring ovulation; DCI's standalone PCOS evidence is thinner than myo-inositol's.

Therapeutic dose: 1,000–2,000 IU/day D3 (repletion to ~30 ng/mL); UL 4,000 IU/day

See ranked Vitamin D products→

• Observational data link low 25(OH)D to lower testosterone, but the association does not establish causation and is confounded by adiposity and general health status.
• Vitamin D receptors are present in testicular tissue, providing a mechanistic rationale — but mechanism has repeatedly failed to translate into testosterone outcomes in randomized trials of replete men.
• Across vitamin D's largest RCTs (VITAL, D-Health), supplementing already-replete adults produced null results on the trials' primary endpoints — repletion of frank deficiency is the supported use.
• Honest read for hormones: correct documented deficiency, which can normalize health broadly — but do not expect topping up an already-normal 25(OH)D to raise testosterone in replete men.

Therapeutic dose: No validated dose — 320 mg/day standard failed to beat placebo even at 960 mg/day

See ranked Saw Palmetto (Serenoa repens) products→

• STEP RCT (NEJM 2006, 225 men, 1 year): saw palmetto produced NO improvement over placebo on urinary symptom score, flow rate, prostate volume, or PSA. The single most-cited rigorous trial — and it was negative.PubMed ↗
• CAMUS RCT (JAMA 2011, 369 men): escalated dosing to 960 mg/day — triple the standard — over 18 months with no benefit vs placebo on any endpoint. Closed the 'just use a higher dose' escape hatch.PubMed ↗
• Cochrane review (2012, 32 RCTs, 5,666 men) confirmed the null: no improvement in urinary symptoms or flow vs placebo. The AUA does not recommend it for BPH.PubMed ↗
• Manufacturer-funded Permixon (hexanic extract) trials report modest symptom benefit but lacked placebo arms — fatal in BPH, where the placebo response is large.

Therapeutic dose: 250 mg twice daily (500 mg/day) of purified extract — preliminary, not validated

• Industry-funded RCT (75 healthy men aged 45–55, 90 days): 500 mg/day purified shilajit (PrimaVie) raised total testosterone ~20% vs placebo. THE trial behind every online claim.PubMed ↗
• No replication exists in healthy young men, where the 'TikTok testosterone' use case lives. The single positive trial ran in a narrow, low-normal-baseline, manufacturer-funded population.
• Safety, not efficacy, is the bigger story: commercial shilajit samples repeatedly test positive for lead, arsenic, and mercury above limits. Only standardized purified extracts have a reasonable safety record.PubMed ↗

Therapeutic dose: 3–10 mg/day (UL 20 mg/day); not an essential nutrient

• RCT in 12 postmenopausal women on a low-boron diet: 3 mg/day roughly doubled serum 17-beta-estradiol and raised testosterone — the tiny depletion-design trial behind the entire boron-hormone narrative.PubMed ↗
• Pilot in 8 healthy men: 10 mg/day for one week raised free testosterone, lowered estradiol, and decreased SHBG — but no placebo arm, one week, 8 men: a pilot, not proof.PubMed ↗
• Boron appears to slow steroid hormone clearance and may interact with SHBG and vitamin D metabolism — biologically plausible, but no large trial shows it raises testosterone in healthy, well-fed men.
• Narrative review concluded the case for boron's hormonal benefit is plausible but rests entirely on small, unreplicated trials from a handful of research groups.PubMed ↗

Therapeutic dose: 1,500–3,500 mg/day dried root powder (only doses tested in trials)

• RCT (57 healthy men, 12 weeks): maca improved self-reported sexual desire vs placebo — but the authors confirmed the effect was NOT explained by any change in testosterone.PubMed ↗
• The hormone trial (56 men, 12 weeks): maca had NO effect on testosterone, LH, FSH, prolactin, or estradiol. This directly refutes 'natural testosterone booster' marketing.PubMed ↗
• 2010 systematic review (4 RCTs) judged the libido evidence 'limited' — small, subjective, low-quality. Maca is a possible libido herb, not a hormone modulator.PubMed ↗

Therapeutic dose: 320 mg/day (BPH trials) — preliminary, not a validated hormone dose

See ranked Pumpkin Seed Oil (Cucurbita pepo) products→

• RCT (76 men, 24 weeks): pumpkin seed oil increased hair count vs placebo in mild-to-moderate androgenetic alopecia — a single small trial, mechanism attributed to phytosterol 5-alpha-reductase inhibition.
• Single-blind RCT vs tamsulosin reported pumpkin seed oil relieved BPH urinary symptoms with no side effects — but it was not as effective as the drug, and the trial lacked a placebo arm.
• The 5-AR / antiandrogen mechanism is plausible but the human evidence is thin and preliminary; no large placebo-controlled confirmation for either prostate or hair outcomes.

Therapeutic dose: No validated standalone dose — usually used in BPH combination products

• Double-blind RCT (100 BPH patients): nettle root extract improved International Prostate Symptom Score vs placebo. Positive but small, single-trial evidence.PubMed ↗
• Mechanism rests on nettle lignans binding sex-hormone-binding globulin (SHBG) — demonstrated in vitro, not a validated clinical hormone effect.
• Most positive data comes from multi-herb BPH combinations (with saw palmetto/pygeum), so nettle's standalone contribution is hard to isolate.

Therapeutic dose: No validated dose for hormone 'balance' — ~100–200 mg/day used in studies

• DIM (and its precursor indole-3-carbinol) shifts urinary estrogen metabolites toward a higher 2-hydroxyestrone : 16-alpha-hydroxyestrone ratio in small studies — a biomarker change, not a clinical outcome.
• The 'estrogen detox / balance' marketing is mechanistic extrapolation: no RCT shows DIM improves a hard clinical endpoint (symptoms, fertility, cancer risk) in healthy people.
• Most human data sits in breast-cancer-prevention biomarker research, not in the hormonal 'estrogen balance' context it is sold for.

Therapeutic dose: 200–400 mg/day elemental (RDA 310–420 mg); supplemental UL 350 mg/day

• Observational and small athlete studies associate higher magnesium status with higher testosterone, but the signal concentrates in deficiency and exercise contexts, not replete sedentary men.
• Magnesium is a cofactor for tyrosine-kinase activity downstream of the insulin receptor and is required for ATP-bound enzymatic reactions — a plausible but indirect route to any hormone effect.
• Repletion of genuine hypomagnesemia reliably normalizes magnesium-dependent processes; supraphysiological dosing in already-replete adults has not shown added hormonal benefit.
• An estimated 48% of Americans consume less than the EAR for magnesium, so any hormone-adjacent benefit is best framed as correcting widespread subclinical insufficiency, not boosting normal levels.

Therapeutic dose: 50–100 mg/day for PMS (RDA 1.3–1.7 mg); UL 100 mg/day — neuropathy risk above

• Pooled review of 9 RCTs in 940 women found B6 up to 100 mg/day roughly doubled the rate of overall PMS improvement vs placebo (OR 2.32); authors called it suggestive, not definitive.PubMed ↗
• B6 is a cofactor for synthesis of serotonin, dopamine, and GABA — the neurotransmitter mechanism proposed for premenstrual symptom relief, though the dose-response is not crisply defined.
• RCT in pregnancy: 25 mg every 8 hours reduced severe nausea scores vs placebo (p<0.01) — addresses a pregnancy symptom, not a sex-hormone outcome; underpins ACOG's first-line recommendation.PubMed ↗
• Safety ceiling matters here: sustained pyridoxine above 100–200 mg/day can cause partly irreversible sensory neuropathy (Schaumburg 1983), so chasing higher 'hormone' doses is actively harmful.PubMed ↗

Therapeutic dose: No validated hormone dose — 15–30 mg/day used in prostate trials

• Lycopene is studied mainly for prostate-cancer risk and antioxidant effects, not for modulating sex hormones. It is not a testosterone or estrogen agent.
• A small pre-prostatectomy trial noted minor shifts (lower free testosterone, higher estradiol) at 30–45 mg/day, but this was in prostate-cancer patients, not a hormone-optimization use case.
• No evidence supports lycopene as a hormone 'booster' or 'balancer' in healthy adults — its prostate relevance is antioxidant/epidemiologic, not endocrine.

Therapeutic dose: No validated dose — no human dosing data of any kind exists

• There are NO published human clinical trials of Fadogia agrestis for testosterone or any hormone outcome. The entire 'test booster' reputation comes from rodent data and podcasts.
• The testosterone claim traces to a single rat study (2005) reporting raised serum testosterone — animal data that has never been replicated in humans.
• Worse: rat studies show dose-dependent TESTICULAR and liver toxicity at higher doses. The animal evidence that supports the hype is the same evidence that flags harm.PubMed ↗